跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2015-003512-20-ES
EUCTR2015-003512-20-ES进行中（未招募）1 期

A Phase III, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy and Safety of Gastric Retentive, Controlled Release Accordion Pill? Carbidopa/Levodopa (AP-CD/LD) to Immediate Release CD/LD in Fluctuating Parkinson?s Disease Patients

Intec Pharma, Ltd.0 个研究点目标入组 460 人开始时间: 2016年3月18日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
460
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •General Study Inclusion Criteria:
  • •1. Men or women between 35 and 85 years of age, inclusive, at initial screening assessment. For the first 100 subjects the age limits are 35-70 years of age, inclusive, at initial screening assessment.
  • •2. Diagnosed with idiopathic Parkinson's disease.
  • •3. Has a good response to levodopa in the opinion of the investigator, and is taking at least 4 doses of levodopa containing medication per day.
  • •4. Anti-PD treatment (such as levodopa formulations, dopamine agonists, selective MAO-B inhibitors, anticholinergic agents or amantadine) at a stable dose in the last 30 days prior to initial screening assessment.
  • •5..Total LD total daily dose of 400 to 1300 mg in at least four divided doses prior to initial screening assessment
  • •6..At least 2.5 hours Off time per day on average (not including morning akinesia), prior to screening. Subject should have at least 1 hour Off time on any given day.
  • •7. Able to adhere to the visit schedule and protocol requirements, and available to complete the study.
  • •8. Able to complete Hauser home diary and can tell the difference between On and Off time.
  • •a. Achieved at least 75% diary concordance with an approved site rater in a 4-hour training session including at least one Off time assessment.
  • •b. Returned a valid 2-day practice diary. A valid diary record will not have more than 4 invalid entries (double or missed entries).
  • •9. Prepared and able to give written (signed and dated) informed consent, which includes compliance with study requirements and restrictions prior to admission to the study.
  • •10. Other than PD, the subject is in satisfactory health, as assessed by physical examination and screening tests. No abnormality on clinical examination and screening tests that in the opinion of the investigator will compromise safety or interfere with study procedures.
  • •11. Living in an area that is within 3 hours driving distance from the study site or is willing to stay in such a place the night before each study site visit.
  • •Inclusion Criteria for the AP-CD/LD Conversion Period:
  • •Subjects will enter the AP-CD/LD Conversion period if at the end of Harmonization and Stabilization period they continue to fulfill the following inclusion criteria:
  • •1. Total LD daily dose of 400 to 1300 mg in at least four divided doses.
  • •2. At least 2.5 hours Off time per day on average (not including morning akinesia) as documented in Hauser home diary. Subjects should have at least 1 hour Off time on any given day.
  • •Inclusion Criteria for Gastroscopy Sub-Study:
  • •Subjects entering the study in the period when gastroscopy examinations are required will have to comply with the following additional requirements:
  • •1. Men or women between 35 and 70 years of age, inclusive, at initial screening assessment.
  • •2. Willingness to undergo two gastroscopies during the study period.
  • •3. No contraindications for sedation.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 140
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 320

排除标准

  • •General Study Exclusion Criteria:
  • •1. Participation in another drug clinical trial within 28 days prior to initial screening assessment (calculated from the previous study's last dosing date).
  • •2. Atypical Parkinsonism (subjects with Parkinsonian features caused by disorder such as multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies or multiple brain infarcts).
  • •3. Significant history of cardiac, pulmonary, hepatic or renal disease or other condition or any major complication/illness which, in the opinion of the investigator, contraindicates his/her participation.
  • •4. Treatment with COMT inhibitors during the last 14 days prior to initial screening assessment.
  • •5. Received within 4 weeks prior to initial screening assessment or planning to take during study participation: non-selective monoamine oxidase (MAO) inhibitors.
  • •6. Previous or planned neurosurgical treatment for PD (e.g., procedures including ablation or deep brain stimulation) during the course of the study.
  • •7. Significant cognitive impairment as defined by the Mini-Mental State Examination (MMSE) score <26.
  • •8. Clinically significant psychiatric illness, including major depression (Hamilton Depression Rating Scale-17 ? 14). Subjects with a lifetime history of suicidal attempt (including an active attempt, interrupted attempt or aborted attempt).
  • •9. History of alcohol or substance abuse within the past 2 years.
  • •10. Unable to swallow large pills (e.g., large vitamin pills).
  • •11. History of melanoma or suspicious skin lesion which could be a melanoma.
  • •12. Narrow-angle glaucoma.
  • •13. History of small bowel or gastric surgery ( except for appendectomy or hernioplasty) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of Crohn's disease, or frequent nausea or emesis, regardless of etiology which, in the opinion of the investigator contraindicates his/her participation in the study.
  • •14. Active peptic ulcer disease or a history of peptic ulcer or upper GI bleeding.
  • •15. Current use of opioids.
  • •16. Symptomatic gastroparesis with frequent vomiting (at least once a week).
  • •17. Concomitant use of NSAIDs and oral steroids within the past 90 days.
  • •18. Allergy to the study drug or any of its excipients, or to Yellow Dye #5 (tartrazine).
  • •19. Women who are pregnant or nursing. Women of childbearing potential who are not willing to use a medically acceptable method of contraception. Medically acceptable methods of contraception that may be used by the subject and /or partner include, but not limited to: oral contraceptive agents, intrauterine devices (IUDs), implantable contraceptives (e.g., Norplant), transdermal hormonal contraceptives (e.g., Ortho-Evra), and injectable contraceptives (e.g., Depo-Provera), condom and /or diaphragm, diaphragm with vaginal spermicide, surgical sterilization (6 months), or postmenopausal females ( no menstrual period for > 2years) or vasectomy ( > 6 months) . The current contraceptive therapy must be maintained for the duration of the study. Hormonal contraceptive therapy must be a stable dose for at least 90 days prior to first study drug administration.
  • •Exclusion Criterion for the Gastroscopy Sub-Study:
  • •Subjects who meet the exclusion criterion listed below will not be eligible for the study during the period of the safety sub-study:
  • •1. Current treatment with drugs known to induce gastric ulcers such as NSAIDs, aspirin at a dose higher than 100 mg per day, iron supplements >30mg/day or bisphosphonates, or treatm

研究者

相似试验

进行中（未招募）
1 期
A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia- Study A - Phase III Safety and Efficacy Study in Primary Insomnia Patients - Study A
EUCTR2010-018413-30-FRMerck & Co., Inc.960
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia – Study A.Primary Insomnia.MedDRA version: 12.1Level: LLTClassification code 10036701Term: Primary insomnia
EUCTR2010-018413-30-SEMSD960
进行中（未招募）
1 期
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia – Study A. - Phase III Safety and Efficacy Study in Primary Insomnia Patients-Study APrimary Insomnia
EUCTR2010-018413-30-FIMSD Finland Oy960
进行中（未招募）
不适用
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients with Primary Insomnia- Study B
EUCTR2010-018414-69-FIMDS Finland Oy945
进行中（未招募）
1 期
Randomized Sitagliptin Withdrawal StudyType 2 Diabetes Mellitus (T2DM)
EUCTR2015-004990-34-LVMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc700